Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATSGO: Prolonged Adjuvant Temozolomide in Glioblastoma
NCT00643825Phase 2Unknown
- Start
- Jan 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms). Primary endpoints: Progression-Free Survival at 6 months and Overall Survival at 6 months. Status: unknown.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00643825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00643825.